Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
BOTHELL, Wash.--(BUSINESS WIRE)--Sep 20, 2021--
Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv). Access to the event can be obtained as follows:
September 21, 2021
6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time
- Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278
- Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company’s website.
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210920005929/en/
CONTACT: For Investors
Senior Vice President, Investor Relations
Vice President, Corporate Communications
KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS
SOURCE: Seagen Inc.
Copyright Business Wire 2021.
PUB: 09/20/2021 05:05 PM/DISC: 09/20/2021 05:06 PM